News on microarrays, multiplexing, genotyping, cytogenetics, gene expression profiling in genetics, genomics, and molecular diagnostics.
The company is hoping its technology can help predict which melanoma patients will respond to checkpoint inhibition using immune-related gene expression signals.
The researchers have used nCounter, an FDA-cleared platform from NanoString Technologies, to develop their gene expression assay for subtype classification.
MammaPrint classifies patients as either high risk or low risk of recurrence over a 10-year period while BluePrint classifies patients by breast cancer subtype.
The test relies on a signature that Almac developed for stratifying breast cancer patients, but which, as the researchers showed, can be used in other cancers as well.
While the study didn't meet its primary endpoint, it showed the potential of transcriptomics to match cancer patients to beneficial treatments.